1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Pulmonary 5-HT
2B receptor expression in fibrotic interstitial lung diseases.
(
- Contribution to journal › Article
- 2021
-
Mark
Pathological insight into 5-ht2b receptor activation in fibrosing interstitial lung diseases
(
- Contribution to journal › Scientific review
- 2018
-
Mark
Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT2B receptor antagonists in vitro - A potential pathway affecting proliferation
(
- Contribution to journal › Article
-
Mark
Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes
(
- Contribution to journal › Article
- 2016
-
Mark
5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo
(
- Contribution to journal › Article